These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34055323)

  • 21. Why the MDGs need good governance in pharmaceutical systems to promote global health.
    Kohler JC; Mackey TK; Ovtcharenko N
    BMC Public Health; 2014 Jan; 14():63. PubMed ID: 24447600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Medicines shortage: Moving towards "regressive" medicine?].
    Dupin N; Bédane C
    Ann Dermatol Venereol; 2015; 142(6-7):391-2. PubMed ID: 25701097
    [No Abstract]   [Full Text] [Related]  

  • 23. Questions raised about whether compulsory licenses get best prices.
    Owens B
    Nat Med; 2015 Apr; 21(4):300. PubMed ID: 25849264
    [No Abstract]   [Full Text] [Related]  

  • 24. [The sustainability of the health system and the pharmaceutical market: A permanent interaction between the cost of medications, the patent system, and disease care].
    Gómez Franco T; Matarín Rodríguez-Peral E; García García F
    Salud Colect; 2020 Oct; 16():e2897. PubMed ID: 33147400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Supply chain management of health commodities for reducing global disease burden.
    Chukwu OA; Ezeanochikwa VN; Eya BE
    Res Social Adm Pharm; 2017; 13(4):871-874. PubMed ID: 27720436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Why drug shortages occur.
    Drug Ther Bull; 2015 Mar; 53(3):33-6. PubMed ID: 25765598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How the MDGs gave up on measuring access to medicines.
    Gotham D; Onarheim KH; Barber MJ
    Lancet Glob Health; 2016 May; 4(5):e296-7. PubMed ID: 27102189
    [No Abstract]   [Full Text] [Related]  

  • 28. Public-private partnerships: new ways to discover, develop and deliver drugs for tropical diseases.
    Hentschel CC
    Southeast Asian J Trop Med Public Health; 2004; 35 Suppl 2():1-4. PubMed ID: 15906625
    [No Abstract]   [Full Text] [Related]  

  • 29. Success of ophthalmic pharmaceutical start-up companies.
    Stewart WC; Kruft B; Nelson LA; Stewart JA
    Acta Ophthalmol; 2018 Mar; 96(2):e266-e268. PubMed ID: 29068525
    [No Abstract]   [Full Text] [Related]  

  • 30. Research on green supply chain coordination strategy for uncertain market demand.
    Cao J; Chen Y; Lu B; Tong C; Zhou G
    Pak J Pharm Sci; 2015 Mar; 28(2 Suppl):687-92. PubMed ID: 25796145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Access to medicines and the rhetoric of responsibility.
    Barry C; Raworth K
    Ethics Int Aff; 2002; 16(2):57-70. PubMed ID: 15709279
    [No Abstract]   [Full Text] [Related]  

  • 32. WTO TRIPS and its effect on the supply and development of medicines in China.
    Tanner JA
    Hong Kong Med J; 2006 Feb; 12(1):84-6. PubMed ID: 16495599
    [No Abstract]   [Full Text] [Related]  

  • 33. Global pharmaceutical development and access: critical issues of ethics and equity.
    Lage A
    MEDICC Rev; 2011 Jul; 13(3):16-22. PubMed ID: 21778954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Globalization in the pharmaceutical industry, Part I.
    Casadio Tarabusi C; Vickery G
    Int J Health Serv; 1998; 28(1):67-105. PubMed ID: 9493754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increasing transparency and accountability in national pharmaceutical systems.
    Paschke A; Dimancesco D; Vian T; Kohler JC; Forte G
    Bull World Health Organ; 2018 Nov; 96(11):782-791. PubMed ID: 30455533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmaceutical industry-led partnerships focused on addressing the global burden of non-communicable diseases: a review of Access Accelerated.
    Umeh CA; Rockers PC; Laing RO; Wagh O; Wirtz VJ
    Public Health; 2020 Apr; 181():73-79. PubMed ID: 31958672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Policies to improve access to pharmaceutical products in shortage: the experience of Iran food and drug administration.
    Yousefi N; Moradi N; Dinarvand R; Ghiasi G; Inanloo H; Peiravian F
    Daru; 2019 Jun; 27(1):169-177. PubMed ID: 30903556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Privatized Pharmaceutical Innovation vs Access to Essential Medicines: A Global Framework for Equitable Sharing of Benefits.
    Burci GL; Gostin LO
    JAMA; 2017 Feb; 317(5):473-474. PubMed ID: 28170485
    [No Abstract]   [Full Text] [Related]  

  • 39. A landmark report on improving medicines for children.
    't Jong GW; Klassen TP; MacLeod SM
    JAMA Pediatr; 2015 Mar; 169(3):204-5. PubMed ID: 25561323
    [No Abstract]   [Full Text] [Related]  

  • 40. Increase in global access to essential drugs sought.
    Banta D
    JAMA; 2000 Jan; 283(3):321, 323. PubMed ID: 10647785
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.